Chromadex Corp (NAGE): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Niagen (NAGE)

Despite the risks of global raw material supply chain disruptions, ChromaDex Corp (NAGE) management is focusing on patents in the field of cellular longevity. The P/S ratio trend clearly demonstrates the balance between market value and actual sales, where 1.40 serves as the current metric level. The brand's high authority in the anti-aging components segment promises stable growth in share prices in the future.

Price-to-Revenue Ratio: ChromaDex Corp. (NAGE) for 03/20/2025 - 11/13/2026

Metric breakdowns and analytics for Niagen (NAGE)

- stock quotes and analyst forecast:
Price ChromaDex Corp.|NAGE - Price Target Chart
- stock exchange capitalization data:
Market Value Niagen|NAGE - Real Price to Acquire Entire Company
- book capitalization indicators:
Book Value per Share ChromaDex|NAGE - Company Book Value|Market Cap to Net Assets Ratio niagenbioscience.com|NAGE - Company Total Assets
- business debt structure and liquidity details:
Debt to Capital Chromadex Corp|NAGE - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio ChromaDex Corporation|NAGE - Company Total Debt|Debt to Book Capital Niagen|NAGE - Company Long-Term Debt|Short-Term Debt Volume ChromaDex|Quick Liquidity Indicator niagenbioscience.com
- company profitability and valuation multiples indicators:
NAGE - Net Profit|Expected Net Income Chromadex Corp|NAGE - Price to Earnings Ratio|Future Price to Earnings Multiple ChromaDex|NAGE - Price/Earnings to Growth Ratio|Company Value to EBITDA Niagen|NAGE - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months ChromaDex|NAGE - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth niagenbioscience.com|NAGE - Earnings growth in current year|Projected earnings per share growth rate for next year Chromadex Corp
- total revenue and sales volume data:
NAGE - Revenue and Sales Volume|Company Expected Sales Volume Niagen|NAGE - Market Cap to Revenue|Market Cap to Projected Revenue Niagen
Summary company analytics:niagenbioscience.com
Mass-produced product of niagenbioscience.com

Chromadex Corp. supplement sales are subject to moderate cyclicality and are sensitive to consumer wellness spending. Analyzing the historical P/S chart, an investor can observe the ratio of market capitalization to annual revenue, which allows for an assessment of the value of each dollar of sales and determines whether the asset's current price is justified by the business's actual cash flows.

Competitors of Chromadex Corp

Market Cap to Sales Volume ISRG|Price-to-Revenue Ratio Danaher DHR|Market Capitalization-to-Revenue Ratio BDX|STE: Market Cap to Revenue|WST - P/S Multiple|Baxter International (BAX) - Price-to-Revenue Ratio|Market Cap to Revenue masimo.com|STVN (Stevanato Group) - P/S Multiple|Price to Sales Teleflex Inc. TFX|Price-to-Revenue Ratio Merit Medical Systems Inc (MMSI)|Nobel Biocare - Market Cap to Revenue Ratio|ICU Medical, Inc. - Market Cap to Revenue|Market Cap to Sales Volume XRAY (dentsplysirona.com)|LMAT - Price-to-Revenue Ratio|Price-to-Revenue Coefficient AtriCure Inc ATRC|STAA: P/S Multiple|Market Cap to Revenue ZimVie Corp|ANGO (AngioDynamics, Inc.) - P/S Multiple|CERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Teknova (TKNO)|MGRM (Monogram Technologies Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Sharps Technology STSS|InfuSystem (INFU) - Price to Sales|UTMD - Price-to-Revenue Ratio|KORU Medical Systems (KRMD) - Market Cap to Revenue|NYXH: P/S Multiple|Microbot Medical, Inc. (MBOT) - P/S Multiple|PDEX (Pro-Dex Corp) - P/S Multiple|Market Cap to Revenue Ratio ZTEK (Zentek Corp)|P/S Multiple ELUT|MLSS - Price to Sales|NEXGEL - Market Cap to Revenue|RVP: Market Cap to Revenue Ratio|HBIO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio FEMY (Femasys Corporation)|MHUA: P/S Multiple|Market Cap to Revenue Predictive Oncology Inc.|Price-to-Revenue Ratio Callan JMB Inc.|Price to Sales Atrion Corp. ATRI|Price-to-Revenue Ratio NeuroMetrix Corp (NURO)